Drug companies and university scientists across the world are working around the clock to find a vaccine against COVID-19 and Plymouth Meeting-based Inovio Pharmaceuticals is among the companies leading the way, write Cristin Flanagan, Riley Griffin, Robert Langreth, and John Lauerman for Bloomberg Businessweek.

While many experts caution that the whole process will take time, some researchers believe a vaccine for the coronavirus could be ready by the end of the year for emergency use.

Most of the programs currently working on the potential vaccine are still in early stages and are a ways off from clinical trials with “blinded” placebo and therapeutic groups.

But thanks to the loosening of some rules that can make the drug approval process slow and cumbersome, some vaccine candidates are now several steps ahead and already in the process of performing trials on humans.

This includes Inovio, which began its human vaccine trial in April. The company, which currently has one of the most promising candidates for the vaccine, is already planning on running larger studies this summer.

Read more about Inovio Pharmaceuticals vaccine progress at Bloomberg Businessweek by clicking here.

You Might Also Like

Inovio’s Experimental COVID-19 Vaccine Given to Philadelphia Volunteers

Bloomberg: Out of 70 Coronavirus Vaccines in Works, Inovio’s Among Three Leading Candidates

Plymouth Meeting-Based Inovio Pharmaceuticals Receives Grant to Develop Vaccine for Newly Identified Coronavirus in China